Overcoming chemotherapy resistance in prostate cancer (Q44640343)

4 December 2017

Overcoming chemotherapy resistance in prostate cancer (English)

1 reference

4 December 2017

1 reference

1 reference

Ravi A Madan

1

1 reference

4 December 2017

Sumanta Kumar Pal

series ordinal

2

1 reference

4 December 2017

Oliver Sartor

series ordinal

3

1 reference

4 December 2017

William L Dahut

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

4 December 2017

Clinical Cancer Research

1 reference

4 December 2017

17

1 reference

4 December 2017

12

1 reference

4 December 2017

3892-3902

1 reference

Microtubule dynamics: mechanism, regulation, and function.

4 December 2017

1 reference

12 December 2020

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

1 reference

12 December 2020

Reversal of docetaxel resistance with bevacizumab and thalidomide

1 reference

12 December 2020

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells

1 reference

12 December 2020

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

1 reference

12 December 2020

Circulating tumor cells as biomarkers in prostate cancer

1 reference

12 December 2020

The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer

1 reference

12 December 2020

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

1 reference

12 December 2020

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

12 December 2020

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

12 December 2020

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

1 reference

12 December 2020

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

1 reference

12 December 2020

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

12 December 2020

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

1 reference

12 December 2020

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family

1 reference

12 December 2020

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

12 December 2020

A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer

1 reference

12 December 2020

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

1 reference

12 December 2020

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

1 reference

12 December 2020

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

1 reference

12 December 2020

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

1 reference

12 December 2020

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

12 December 2020

The roles of beta-tubulin mutations and isotype expression in acquired drug resistance

1 reference

12 December 2020

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

1 reference

12 December 2020

Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

1 reference

12 December 2020

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

1 reference

12 December 2020

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

1 reference

12 December 2020

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

1 reference

12 December 2020

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

12 December 2020

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

1 reference

12 December 2020

Taxol-induced polymerization of purified tubulin. Mechanism of action

1 reference

12 December 2020

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

1 reference

12 December 2020

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

12 December 2020

Effects of a microtubule stabilizing agent on the response of platelets to vincristine

1 reference

12 December 2020

Intermittent chemotherapy for metastatic hormone refractory prostate cancer

1 reference

12 December 2020

Phase II study of sunitinib in men with advanced prostate cancer.

1 reference

12 December 2020

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

1 reference

12 December 2020

Targeting continued androgen receptor signaling in prostate cancer

1 reference

12 December 2020

Dynamic properties of microtubules at steady state in the presence of taxol

1 reference

12 December 2020

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

12 December 2020

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

1 reference

12 December 2020

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

1 reference

12 December 2020

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

12 December 2020

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

12 December 2020

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

1 reference

12 December 2020

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

1 reference

12 December 2020

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics

1 reference

12 December 2020

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

12 December 2020

Increased expression of class III beta-tubulin in castration-resistant human prostate cancer

1 reference

12 December 2020

Abiraterone. Cougar Biotechnology.

1 reference

12 December 2020

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

12 December 2020

Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines

1 reference

12 December 2020

10.1158/1078-0432.CCR-10-2654

Identifiers

DOI

1 reference

release_iyefzlci2femfpazbnmocb4f4y

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iyefzlci2femfpazbnmocb4f4y

24 November 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/iyefzlci2femfpazbnmocb4f4y

24 November 2022

mapped directly with Wikidata item

1 reference